Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Non‐small cell lung cancer in China
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging
Resolving the spatial distribution of RNA and protein in tissues at subcellular resolution is a
challenge in the field of spatial biology. We describe spatial molecular imaging, a system …
challenge in the field of spatial biology. We describe spatial molecular imaging, a system …
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and …
Background Targeted inhibition of the PD-L1–PD-1 pathway might be further amplified
through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune …
through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune …
Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics
Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3 …
Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the
first-line treatment of advanced non-small-cell lung cancer with programmed cell death …
first-line treatment of advanced non-small-cell lung cancer with programmed cell death …
TKIs in combination with immunotherapy for hepatocellular carcinoma
Introduction The treatment landscape of hepatocellular carcinoma (HCC) has significantly
changed over the last 5 years with multiple options in the frontline, second line, and beyond …
changed over the last 5 years with multiple options in the frontline, second line, and beyond …
Top 10 challenges in cancer immunotherapy
Cancer immunotherapy is a validated and critically important approach for treating patients
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …
Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC
Background The efficacy and safety of the anti–programmed death ligand 1 (PD-L1)
monoclonal antibody atezolizumab, as compared with those of platinum-based …
monoclonal antibody atezolizumab, as compared with those of platinum-based …